Liraglutide (Victoza, Saxenda)

FDA-approved context Weight Loss & Metabolism 3 sources

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that shares 97% sequence identity with human GLP-1. It is FDA-approved for the treatment of type 2 diabetes and chronic weight management, working by stimulating insulin secretion, inhibiting glucagon release, and delaying gastric emptying.

01Dosing reference

Amount

1.2-1.8 mg/day (Diabetes) or 3.0 mg/day (Weight Loss)

Frequency

Once daily

Cycle

Continuous daily use as prescribed

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

GLP-1 Receptor Activation

Liraglutide binds to and activates the GLP-1 receptor, a cell-surface receptor found in the pancreas, brain, and gastrointestinal tract.

Metabolic Regulation

It stimulates glucose-dependent insulin secretion from pancreatic beta cells and suppresses inappropriate glucagon secretion from alpha cells.

Appetite Suppression and Gastric Emptying

It slows gastric emptying and acts on appetite centers in the brain to increase satiety and reduce food intake, leading to weight loss.

03Human evidence

Significant weight loss in obese individuals

In the SCALE clinical trials, patients taking 3.0 mg daily of liraglutide achieved significantly greater weight loss compared to placebo over 56 weeks.

Improved glycemic control in type 2 diabetes

The LEAD clinical trial program demonstrated that liraglutide (up to 1.8 mg daily) significantly reduced HbA1c levels in patients with type 2 diabetes.

Cardiovascular risk reduction

The LEADER trial showed that liraglutide significantly reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular risk.

04Preclinical evidence

Beta-cell preservation

Animal models of diabetes showed that liraglutide promotes beta-cell proliferation and inhibits apoptosis, potentially preserving pancreatic function.

Neuroprotective effects

In rodent models of Alzheimer's disease, liraglutide demonstrated neuroprotective properties, reducing amyloid plaque burden and improving memory function.

05What is known vs. unknown

Reasonably established

Liraglutide is FDA-approved for type 2 diabetes (Victoza) and weight management (Saxenda).
It requires daily subcutaneous injections due to its half-life of approximately 13 hours.
It effectively lowers blood glucose levels in a glucose-dependent manner, minimizing the risk of hypoglycemia.
It promotes significant weight loss by reducing appetite and slowing gastric emptying.
It has demonstrated cardiovascular benefits in patients with type 2 diabetes.

Unknowns & limits

The long-term effects on pancreatic health, including the potential risk of pancreatitis, require ongoing monitoring.
Its efficacy and safety in pediatric populations for weight management are still being fully established.
The potential for thyroid C-cell tumors, observed in rodents, remains a theoretical risk in humans, leading to a black box warning.

06Safety & regulatory context

Regulatory statusLiraglutide is an FDA-approved prescription medication. Common side effects include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation, which often subside over time. It carries a black box warning for the risk of thyroid C-cell tumors, based on findings in rodents; therefore, it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other risks include acute pancreatitis, gallbladder disease, and hypoglycemia when used with insulin secretagogues.

07Compared with Semaglutide

Liraglutide (Victoza, Saxenda) vs. Semaglutide

Key difference

Liraglutide requires daily injections, whereas semaglutide has a longer half-life allowing for once-weekly injections. Semaglutide generally produces greater weight loss.

When researchers discuss each

Liraglutide is discussed when a daily dosing regimen is preferred or when evaluating the foundational GLP-1 therapies, while semaglutide is discussed for its superior efficacy and convenient weekly dosing.

08Glossary

GLP-1 Receptor Agonist

A class of medications that mimic the action of the naturally occurring hormone GLP-1 to regulate blood sugar and appetite.

Gastric Emptying

The process by which food leaves the stomach and enters the small intestine; slowing this process increases feelings of fullness.

HbA1c

A blood test that measures average blood sugar levels over the past 2 to 3 months.

Subcutaneous Injection

An injection administered into the fat layer just under the skin.

09Knowledge check

Q1What is the primary mechanism by which liraglutide promotes weight loss?

Q2Why does liraglutide carry a black box warning?

Q3Which statement best reflects a documented limitation in the evidence about liraglutide from the supplied dossier?

Q4According to the dossier, in which context is liraglutide most likely to be discussed relative to semaglutide?

Q5Which patient history is specifically identified in the dossier as a contraindication to liraglutide?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.